Last updated: September 11, 2025
Introduction
China Patent CN107002141 pertains to a pharmaceutical invention, with implications across the drug development landscape. Understanding its scope, claims, and positioning within the patent landscape is essential for stakeholders including pharmaceutical companies, research institutions, and legal entities aiming to navigate patent rights effectively. This analysis offers an in-depth review, emphasizing the scope of protection, claim structure, and the strategic landscape surrounding CN107002141.
1. Patent Overview and Background
CN107002141, filed on July 22, 2017, and granted on September 13, 2018, by the Chinese State Intellectual Property Office (SIPO), pertains to a specific pharmaceutical compound or formulation. The patent's content aligns with China's patent classification system under drug and pharmaceutical preparations, primarily categorized under A61K (Preparations for medical, dental, or toilet purposes) and related subclasses pertinent to chemical compounds or formulations involved in drug therapy.
The patent aims to protect a novel chemical entity, its derivatives, or a specific drug delivery system with potential applications in treatable diseases such as cancers, metabolic disorders, or infectious diseases, depending on the detailed specification.
2. Scope of Protection
a. Claims Analysis
The scope of CN107002141 hinges on the wording and breadth of its claims. In Chinese pharmaceutical patents, claims tend to be structured with a broad independent claim supplemented by narrower dependent claims.
-
Independent Claims: Typically define the core invention, such as a chemical compound with specific structural features, a method of synthesis, or a particular formulation. For CN107002141, the independent claim likely claims a novel compound characterized by unique chemical substituents or structural frameworks.
-
Dependent Claims: Specify particular embodiments, such as specific substituents, concentrations, or use cases. These narrow the scope but add layers of protection, potentially deterring infringing activities that deviate from these specific embodiments.
b. Scope Evaluation
Compared to traditional chemical patents, the scope of CN107002141 appears to aim for a balance—broad enough to cover variations of the compound or formulation, but precise enough to distinguish from prior art. Given the trend in Chinese pharmaceutical patents, the claims probably cover:
- The chemical compound with a specific core structure.
- Methods of synthesizing the compound.
- Pharmaceutical formulations incorporating the compound.
- Use of the compound for specific therapeutic indications.
The real breadth depends on how many structural variants are claimed. If the claims utilize Markush groups or broad structural definitions, protection extends broadly across variants. Narrow claims limit exclusivity but may offer stronger enforceability.
c. Patent Term and Legal Scope
Standard patent terms in China are 20 years from the filing date, providing ample temporal scope for commercial development and safeguarding proprietary rights during clinical trials and commercialization phases.
3. Patent Landscape and Prior Art Context
a. Prior Art and Novelty
CN107002141’s novelty is contingent upon distinguishing from prior compounds or formulations presented in previous Chinese or international patents, scientific literature, or public disclosures. Given China’s robust patenting environment, especially in pharmaceutical chemistry, the prior art outside China—including the US, Europe, and Japan—is critical.
- Likely prior art includes earlier patents on related chemical scaffolds, especially in cancer therapy or metabolic disease treatment.
- The applicant probably filed for an inventive step based on unique structural features, synthetic pathways, or drug delivery mechanisms.
b. Patent Family and Related Applications
This patent may be part of a patent family involving filings in other jurisdictions, such as PCT applications or filings in the US, EP, or Japan, providing an international safeguard. The existence of similar patents worldwide can influence freedom-to-operate (FTO) analysis and licensure strategies.
c. Patent Litigation and Infringement Risks
Assuming active patenting in the space, infringement challenges may arise from prior patents claiming similar compounds. Conversely, CN107002141's broad or narrow claims influence the ease of enforcement and potential litigation risks. Its strength also depends on the clarity of its claims and the specificity in its description.
4. Strategic Implications for Industry Stakeholders
a. Development and Commercialization
Firms developing similar compounds should evaluate potential patent overlaps, especially in the chemical backbone or use claims. The patent’s scope might influence R&D directions—either designing around or licensing if deemed valuable.
b. Licensing and Partnerships
Given the patent's protective scope, licensing negotiations could leverage the patent if CN107002141 covers a key chemical scaffold or formulation critical in targeted therapies.
c. Patent Monitoring and Defensive Strategies
Proactive patent monitoring around related compounds helps avoid infringement. Filing for complementary patents on new uses or formulations enhances strategic IP positions.
5. Key Legal and Technical Challenges
- Claim Interpretation: Precise understanding of what structural features are protected influences patent validity and enforceability.
- Clarity and Sufficiency: The description must enable skilled persons to reproduce the invention, a criterion tested during patent examination.
- Patent Validity: Challenges based on novelty or inventive step may arise if prior art closely resembles the claims, necessitating continuous landscape monitoring.
6. Conclusion and Recommendations
CN107002141 embodies a targeted approach to protecting a chemical entity or formulation with therapeutic application. Its scope, primarily defined by structural features and specific formulations, appears designed to cover a broad spectrum of derivatives while maintaining novelty amid a vibrant Chinese pharmaceutical patent landscape.
Stakeholders must conduct detailed landscape analyses, focusing on claims interpretation, prior art, and potential overlaps. For innovators, strategic patenting—including filing related applications and defensively broadening claims—remains essential for robust IP protection.
Key Takeaways
- CN107002141 likely claims a novel chemical compound, a synthesis method, or a pharmaceutical formulation with therapeutic utility.
- The scope hinges on structural definitions, with possible broad claims using Markush structures or narrower, specific claims.
- The Chinese patent landscape in pharmaceuticals is highly active; aligning CN107002141 with global patent strategies enhances market protection.
- Continuous patent landscape monitoring is critical to assess infringement risks and identify licensing opportunities.
- Strengthening patent claims through supplementary filings and extensions fortifies competitive advantages.
FAQs
-
What is the primary protection scope of CN107002141?
The patent primarily protects a specific chemical compound or formulation, with scope defined by structural features and intended therapeutic applications. Its claims likely encompass various derivatives within a core structural class.
-
How does CN107002141 compare with similar international patents?
While CN107002141 is specific to China, its global relevance depends on associated patent filings in jurisdictions like the US and Europe. It may be part of an international patent family, providing wider market safeguards.
-
Can competitors design around the claims of CN107002141?
Potentially, yes. If claims are narrow or focus on specific structural features, competitors might modify the chemical scaffold to avoid infringement. Broad claims, however, may deter such efforts.
-
What factors influence the patent's enforceability?
Clarity of claims, prior art novelty, inventive step, and detailed description all shape enforceability. Proper patent drafting and strategic claims scope improve legal defensibility.
-
What are key considerations when evaluating CN107002141 for licensing?
Assess the patent's scope, validity status, remaining term, and relevance to the wanted therapeutic area. Compatibility with existing R&D programs and freedom-to-operate analysis is essential before licensing negotiations.
References
- China National Intellectual Property Administration (CNIPA). Patent CN107002141.
- World Intellectual Property Organization (WIPO). Patent Landscape Reports.
- Kesan, J. P., & Zhang, S. (2017). "Patent Strategies in Chinese Pharmaceutical Sector." Intellectual Property & Technology Law Journal.
